GeNeuro’s Temelimab Phase 2 Multiple Sclerosis Trial Cleared to Continue Following Planned Data Safety Monitoring Board Meeting
- Dow hits milestone, S&P breaks record high on tech rally
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Dollar heads for second weekly loss on Fed's lower-for-longer stance
- Apple (AAPL) May Scrap iPhone Mini Next Year, New Lineup to Focus on Camera Quality, Says Top Analyst
- Oil rises above $67 in fifth day of gains on demand hopes
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
- DSMB confirms higher doses of temelimab in ProTEct-MS Phase 2 study are well tolerated
- Study conducted at Karolinska Institutet’s Academic Specialist Center (ASC) in Stockholm
- Phase 2 top-line results on track to be reported in Q1 2022
GENEVA--(BUSINESS WIRE)-- Regulatory News:
GeNeuro (Paris: GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that the independent Drug Safety Monitoring Board (DSMB) has concluded the Phase 2 trial of temelimab in MS patients should continue as planned without modification. This follows a pre-determined review of the first 8 patients treated with temelimab for 2 months at doses of 18, 36 and 54 mg/kg. The study, called ProTEct-MS, is being conducted at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm (Sweden).
Temelimab is a monoclonal antibody designed to neutralize a pathogenic retroviral envelope protein, pHERV-W Env. Positive results with temelimab have already been achieved in two clinical studies, CHANGE-MS and ANGEL-MS, using a dose of 18mg/kg.
“Our previous clinical studies have demonstrated that temelimab administration is safe and demonstrated positive results on markers of disability progression at 18 mg/kg in patients, so it is now important to define the optimal dose in preparation for the planned Phase III study,” said Prof. David Leppert, Chief Medical Officer of GeNeuro. “We are delighted to have the tolerability of the higher doses of temelimab confimed as a further step in our path to deliver a treatment against the critical unmet medical need of blocking disability progression in MS.”
Patient enrolment into ProTEct-MS was recently completed with a cohort of 42 patients being treated for 48 weeks with temelimab (18, 36 and 54 mg/kg) vs. placebo. The double-blind placebo-controlled study has been designed to assess safety, tolerability and efficacy measures based on the latest biomarkers associated with disease progression and will have results in 1Q2022. Patients included in the study had confirmed disability progression without relapses following previous treatment with the anti-CD20 drug rituximab, a highly potent and efficacious drug against acute disease activity (relapses and brain lesion formation).
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by human endogenous retroviruses (HERVs), which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.
For more information, visit: www.geneuro.com
This press release contains certain forward - looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.
Chairman and CEO
+41 22 552 4800
Louis-Victor Delouvrier / Mathilde Bohin (investors)
+33 1 44 71 98 52
Nicolas Merigeau (media)
+33 1 44 71 94 98
Mike Sinclair (media)
+44 20 7318 2955
Chris Maggos (investors)
+41 79 367 6254
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ault Global Holdings Reports 2020 Year-End Financial Results
- DLR Kredit A/S - endelige obligationsvilkår (DK0006352786 - 1,5% B 2053)
- SMIC Announces First Quarter 2021 Webcast Conference Call
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!